20/05/2024  21:59:55 Var. +0.52 Volume Denaro- Lettera- Capitalizzazione di mercato Dividend Y. Rapporto P/E
16.81USD +3.16% 299,635
Fatturato: 5.01 mill.
-Quantità in denaro: - -Quantità in lettera: - 19.04 bill.USD - -

Descrizione business

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Kåre Schultz
Consiglio di amministrazione
Eli Kalif, David M. Stark, Dr. Hafrun Fridriksdottir, Eli Shani, Eric Drapé, Galia Inbar, Lori Queisser, Mark Sabag, Nir Baron, Richard Daniell, Sven Dethlefs
Consiglio di sorveglianza
Dr. Sol J. Barer, Amir Elstein, Dr. Perry D. Nisen, Dr. Tal Zaks, Gerald M. Lieberman, Janet S. Vergis, Jean-Michel Halfon, Kåre Schultz, Nechemia J. Peres, Prof. Ronit Satchi-Fainaro, Roberto A. Mignone, Rosemary A. Crane
 

Dati aziendali

Name: Teva Pharmaceuticals Industries Ltd.
Indirizzo: 5 Basel St.,Petach Tikva 49131, Israel
Telefono: +972-3-914-8171
Fax: +972-3-914-8678
E-mail: -
Internet: www.tevapharm.com
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: 88.20%
Data dell'IPO: -

Rapporti con gli investitori

Name: Kevin C. Mannix
IR telefono: +215-591-8912
IR Fax: -
IR e-mail: kevin.mannix@tevapharm.com

Principali azionisti

Freefloat
 
88.20%
Capital Research and Management Company
 
11.80%